Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 138

Sort by

Sort Order Select

Journal Articles

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis

Aaron S. Rosenberg, Emanual Maverakis, Caitlin Costello, Elizabeth A. Brem, Matthew Joseph Wieduwilt, Guillaume Luxardi, Paul Kaesberg, Keon Abedi, Samantha Herbert, Joseph Tuscano

Blood Neoplasia (2025) 2 (3): 100067.

https://doi.org/10.1016/j.bneo.2025.100067

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

Suravi Raychaudhuri, Ted A. Gooley, Allegra Rasmussen, Kim Quach, Eva Gill, Anna B. Halpern, Jacob S. Appelbaum, Cristina M. Ghiuzeli, Paul C. Hendrie, Ryan D. Cassaday, Roland B. Walter, Mary-Elizabeth M. Percival

Blood Neoplasia (2025) 2 (3): 100085.

https://doi.org/10.1016/j.bneo.2025.100085

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 2 trial of daratumumab, cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma

Edvan de Queiroz Crusoé, Joanna Suzana Leal Ribeiro dos Santos, Juliana de Andrade Santos, Herbert Henrique de Melo Santos, Allan de Souza Santos, Larissa Ferreira Lucas, Cristiane Almeida Requião de Pinna, Paula Nogueira Caldas Freire, Adriano Araujo de Jesus, Alessandro de Moura Almeida, Daniela Dourado Dutra, Marcos Fonseca Chaves, Jamile Souza Nicanor, Marco Aurelio Salvino, Maria da Gloria Bomfim Arruda, Vania Hungria

Blood Neoplasia (2025) 2 (3): 100081.

https://doi.org/10.1016/j.bneo.2025.100081

Published: 2025

Includes: Supplemental data

Journal Articles

TYK2 is essential for the therapeutic effect of IFN-α in Jak2 V617F-induced murine myeloproliferative neoplasms

Blood Neoplasia (2025) 2 (3): 100087.

https://doi.org/10.1016/j.bneo.2025.100087

Published: 2025

Includes: Supplemental data

Journal Articles

Tumor-associated myeloid cells support murine T-ALL in the central nervous system via integrin signaling

Ryan S. Humphrey, Seohee Nam, Dennis C. Wylie, Lauren I. R. Ehrlich

Blood Neoplasia (2025) 2 (3): 100095.

https://doi.org/10.1016/j.bneo.2025.100095

Published: 2025

Includes: Supplemental data

Journal Articles

Quality of life, fatigue, depression, attention deficits, and pain after childhood Langerhans cell histiocytosis

Malin Sveijer, Désirée Gavhed, Helena Hertzberg, Eric Zander, Jan-Inge Henter, Tatiana von Bahr Greenwood

Blood Neoplasia (2025) 2 (3): 100098.

https://doi.org/10.1016/j.bneo.2025.100098

Published: 2025

Includes: Supplemental data

Journal Articles

Ambroxol induces myeloma cell death by inhibiting autophagy

Yutaka Hattori, Hiromu Sugiyama, Yamato Miyashita, Shinsuke Shibata, Taiga Okaue, Yoshinao Matsumoto, Taketo Yamada, Tomofumi Yamamoto, Takashi Yamaguchi, Kohei Yamazaki, Hisako Kunieda, Hideyuki Saya, Maiko Matsushita

Blood Neoplasia (2025) 2 (3): 100100.

https://doi.org/10.1016/j.bneo.2025.100100

Published: 2025

Includes: Supplemental data

Journal Articles

Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab

Charles Pei, Zeinab El Boghdadly, Lisa Blackburn, Nidhi Sharma, Naresh Bumma, Abdullah M. Khan, Srinivas Devarakonda, Elvira Umyarova, Don Benson, Ashley Rosko, Francesca Cottini

Blood Neoplasia (2025) 2 (3): 100097.

https://doi.org/10.1016/j.bneo.2025.100097

Published: 2025

Includes: Supplemental data

Journal Articles

Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies

Emil Ramsø Kyvsgaard, Trine Lønbo Grantzau, Mia Dahl Sørensen, Michael Boe Møller, Lene Dissing Sjø, Morten Grauslund, Trine Trab, Linea Cecilie Melchior, Lærke Sloth Andersen, Caroline Riley, Carsten U. Niemann, Jacob Haaber, Thomas Stauffer Larsen, Michael Roost Clausen, Kirsten Grønbæk, Martin Hutchings, Simon Husby

Blood Neoplasia (2025) 2 (3): 100096.

https://doi.org/10.1016/j.bneo.2025.100096

Published: 2025

Includes: Supplemental data

Journal Articles

A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma

Yuan Xiao Zhu, Soumya Dutta, Gregory J. Ahmann, Laura Bruins, Mariano Arribas, Xianfeng Chen, Abhigna Polavarapu, Jonathan Chapman, Isaac Lopez, Marta Chesi, P. Leif Bergsagel, Abhishek Singharoy, Rafael Fonseca, Lisa M. Rimsza

Blood Neoplasia (2025) 2 (3): 100099.

https://doi.org/10.1016/j.bneo.2025.100099

Published: 2025

Includes: Supplemental data

Journal Articles

Magnetic resonance spectroscopy–based detection of response to therapy targeting glutaminolysis in lymphoma

Kavindra Nath, Pradeep K. Gupta, Shengchun Wang, Alexander A. Shestov, Neil Sen, Shilpa Rao, Stepan Orlovskiy, Cosimo Lobello, David Rushmore, Fernando Arias-Mendoza, Johnvesly Basappa, David S. Nelson, Mariusz A. Wasik

Blood Neoplasia (2025) 2 (3): 100105.

https://doi.org/10.1016/j.bneo.2025.100105

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources

Chenyu Lin, Smitha Sivaraman, Gautam Sajeev, Yan Song, Chunyi Xu, Chujun He, James E. Signorovitch, Heayoung Shin, Xiao-Ying Tang, Mei-Jie Zhang, Linda J. Burns, Ronit Simantov, Mitchell E. Horwitz

Blood Neoplasia (2025) 2 (3): 100104.

https://doi.org/10.1016/j.bneo.2025.100104

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma

Nikita K. Dave, Veronica Carvajal, Alex C. Watts, Jordan S. Carter, Michael Cook, Colin Thomas, Donald E. Tsai, Stephen J. Schuster, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Wei-Ting Hwang, Daniel J. Landsburg, Sunita D. Nasta

Blood Neoplasia (2025) 2 (3): 100102.

https://doi.org/10.1016/j.bneo.2025.100102

Published: 2025

Includes: Supplemental data

Journal Articles

Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience

Blood Neoplasia (2025) 2 (3): 100103.

https://doi.org/10.1016/j.bneo.2025.100103

Published: 2025

Journal Articles

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi-Sharifi, Sameem Abedin, Monzr M. Al Malki, Vijaya Raj Bhatt, Prabhu Rajagopalan, Min Tang, Sandra E. Wiley, Richard G. Ghalie, Matthew S. Davids

Blood Neoplasia (2025) 2 (3): 100108.

https://doi.org/10.1016/j.bneo.2025.100108

Published: 2025

Includes: Supplemental data

Journal Articles

Checkpoint immunotherapy is associated with preferential activation of tumor antigen–specific CD4 + T cells in MDS

Elizabeth A. Griffiths, Pragya Srivastava, Eduardo Cortes Gomez, Junko Matsuzaki, Kunle Odunsi, Laura W. Dillon, Devdeep Mukherjee, Christopher S. Hourigan, Jacqueline Peng, Shovik Bandyopadhyay, Kai Tan, Kristopher M. Attwood, Joseph B. Kuechle, Prashant K. Singh, Jianmin Wang, Michael J. Nemeth

Blood Neoplasia (2025) 2 (3): 100106.

https://doi.org/10.1016/j.bneo.2025.100106

Published: 2025

Includes: Supplemental data

Journal Articles

Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain

Elias Lagonik, Elyse C. Page, John B. Bruning, Laura N. Eadie, Susan L. Heatley, Matthew Greenwood, Chun Y. Fong, Andrew S. Moore, David T. Yeung, Timothy P. Hughes, Deborah L. White

Blood Neoplasia (2025) 2 (3): 100109.

https://doi.org/10.1016/j.bneo.2025.100109

Published: 2025

Includes: Supplemental data

Journal Articles

Temporal clonal relatedness between myeloid neoplasm and nodal T-follicular helper cell lymphoma: a retrospective study

Mingfei Yan, Robert Stuver, Kai Shiang Lin, William T. Johnson, Steven M. Horwitz, Ahmet Dogan, Wenbin Xiao

Blood Neoplasia (2025) 2 (3): 100112.

https://doi.org/10.1016/j.bneo.2025.100112

Published: 2025

Includes: Supplemental data

Journal Articles

Elevated B12 serum levels are associated with the presence of Clonal Hematopoiesis

Varun Gupta, Peter D. Lyon, Aristeidis G. Telonis, Marina Konopleva, Luisa Cimmino

Blood Neoplasia 100136.

https://doi.org/10.1016/j.bneo.2025.100136

Published: 2025

Includes: Supplemental data

Journal Articles

Developmental Stage and Cellular Context Determine Oncogenic and Molecular Outcomes of Ezh2 Y641F Mutation in Hematopoiesis

Sarah M. Zimmerman, Samantha J. Procasky, Sofia R. Smith, Jie-Yu Liu, Chad Torrice, George P. Souroullas

Blood Neoplasia 100137.

https://doi.org/10.1016/j.bneo.2025.100137

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

Phase 2 trial of daratumumab, cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma

TYK2 is essential for the therapeutic effect of IFN-α in Jak2 V617F-induced murine myeloproliferative neoplasms

Tumor-associated myeloid cells support murine T-ALL in the central nervous system via integrin signaling

Quality of life, fatigue, depression, attention deficits, and pain after childhood Langerhans cell histiocytosis

Ambroxol induces myeloma cell death by inhibiting autophagy

Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab

Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies

A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma

Magnetic resonance spectroscopy–based detection of response to therapy targeting glutaminolysis in lymphoma

Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources

Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma

Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Checkpoint immunotherapy is associated with preferential activation of tumor antigen–specific CD4 + T cells in MDS

Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain

Temporal clonal relatedness between myeloid neoplasm and nodal T-follicular helper cell lymphoma: a retrospective study

Elevated B12 serum levels are associated with the presence of Clonal Hematopoiesis

Developmental Stage and Cellular Context Determine Oncogenic and Molecular Outcomes of Ezh2 Y641F Mutation in Hematopoiesis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only